Allos AI

Allos AI develops a causal AI platform for pharmaceutical companies reformulating complex small-molecule medicines. It models how formulation, dosing, delivery and patient biology interact, helping drug developers and generic manufacturers explore improvements to existing medicines. The Allos platform supports formulation development, manufacturing scale-up, technology transfer and clinical studies. Teams can simulate interventions before running experiments and use real-world health data to inform patient stratification and study design.

Co-founder and CEO Aditya Varna Iyer leads a team combining AI, physics and pharmaceutical development expertise. Allos uses a lab-in-the-loop approach: physics-informed causal models incorporate process evidence and experimental feedback to guide subsequent work. Its models account for known constraints and quantify uncertainty, while experts validate assumptions and approve changes. Versioned models and linked inputs, decisions and assumptions provide traceability for quality review.

Allos works with pharmaceutical partners to modernize legacy drugs and advance stalled development programs. In 2026, the company reported processing more than 100,000 patient records across multiple studies, supporting validation and real-world evidence programs. It also announced $5 million in seed financing led by Oxford Science Enterprises that year to commercialize its platform and expand formulation development and data science.